ALK-Abelló (ALK B) Stock Overview
An allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALK B from our risk checks.
ALK B Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 206.60 |
| 52 Week High | DKK 237.60 |
| 52 Week Low | DKK 131.40 |
| Beta | 0.63 |
| 1 Month Change | -6.77% |
| 3 Month Change | -9.47% |
| 1 Year Change | 56.63% |
| 3 Year Change | 92.37% |
| 5 Year Change | 68.10% |
| Change since IPO | 504.98% |
Recent News & Updates
Recent updates
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jan 23
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
Dec 08ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
Nov 15Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Oct 11ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
Jul 23ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jun 17Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?
May 04Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors
Apr 16
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Shareholder Returns
| ALK B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 0.4% | 1.2% | 1.1% |
| 1Y | 56.6% | -37.8% | -7.1% |
Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned -43.3% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned -14.3% over the past year.
Price Volatility
| ALK B volatility | |
|---|---|
| ALK B Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DK Market | 8.8% |
| 10% least volatile stocks in DK Market | 3.0% |
Stable Share Price: ALK B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: ALK B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,613 | Peter Halling | www.alk.net |
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy.
ALK-Abelló A/S Fundamentals Summary
| ALK B fundamental statistics | |
|---|---|
| Market cap | DKK 45.77b |
| Earnings (TTM) | DKK 1.20b |
| Revenue (TTM) | DKK 6.31b |
Is ALK B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALK B income statement (TTM) | |
|---|---|
| Revenue | DKK 6.31b |
| Cost of Revenue | DKK 2.07b |
| Gross Profit | DKK 4.24b |
| Other Expenses | DKK 3.05b |
| Earnings | DKK 1.20b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | 5.40 |
| Gross Margin | 67.24% |
| Net Profit Margin | 18.96% |
| Debt/Equity Ratio | 2.6% |
How did ALK B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/08 11:41 |
| End of Day Share Price | 2026/04/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ingildsen | DNB Carnegie |